Monica Dejulio
Family · Seattle, WANPI 1750858882
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,114 of the $2,653 with a category attached, or 79.7%. It is spread thinly across 31 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,562 and has fallen 97.1% since, to $74 in 2025. Among family clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $29.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$381
- Taiho Oncology, Inc.$236
- AstraZeneca$221
- Takeda Pharmaceuticals U.S.A., Inc.$194
- Astellas Pharma US Inc$173
- Pfizer$163
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,11480%
- Education$53920%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 7 | $381 |
| Taiho Oncology, Inc. | 11 | $236 |
| AstraZeneca | 9 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $194 |
| Astellas Pharma US Inc | 5 | $173 |
| Pfizer | 4 | $163 |
| Array Biopharma Inc | 5 | $138 |
| Amgen | 1 | $125 |
| Genmab U.S., Inc. | 4 | $117 |
| Johnson & Johnson | 2 | $100 |
| Tempus AI, Inc | 3 | $74 |
| Coherus Oncology, Inc. | 3 | $73 |
| GSK | 3 | $72 |
| Aimmune Therapeutics, Inc. | 2 | $56 |
| Incyte Corporation | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Novartis | 2 | $46 |
| Bayer | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Accord Healthcare, Inc. | 2 | $37 |
| Tersera Therapeutics LLC | 2 | $36 |
| Rigel Pharmaceuticals, Inc. | 1 | $33 |
| Blueprint Medicines Corporation | 1 | $31 |
| Acrotech Biopharma Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Organon | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $18 |
| Boston Scientific | 1 | $16 |
How this compares
$2,653 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.
Other family in Seattle
- Kevan PettersonSeattle$56K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
- Lilly SilvaSeattle$9K
- Yeo Jin MoonSeattle$6K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.